Vaccinex, Inc.: financial reference
Explore Vaccinex, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.
Context from the filing
Vaccinex's 2023 and 2024 basic denominator already includes issued but unexercised pre-funded warrants; they must not be added again as dilution. Other common-stock equivalents are excluded during losses. Share and per-share amounts retrospectively reflect the September 2023 one-for-15 and February 2024 one-for-14 reverse splits. Dollar losses are displayed in thousands; shares and per-share amounts are unscaled. Selected values remain on that reported basis. Read the source filing.
Reported financial histories
Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.
| Measure | Period start | Period end | Value | Unit | Filed |
|---|---|---|---|---|---|
| Total assets | At date | 2024-12-31 | 2,596,000 | USD | 2025-04-15 |
| Total liabilities | At date | 2024-12-31 | 5,084,000 | USD | 2025-04-15 |
| Stockholders equity | At date | 2021-12-31 | 7,412,000 | USD | 2022-03-31 |
| Cash and cash equivalents | At date | 2024-12-31 | 1,107,000 | USD | 2025-04-15 |
| Net income or loss | 2024-01-01 | 2024-12-31 | -18,634,000 | USD | 2025-04-15 |
| Operating cash flow | 2024-01-01 | 2024-12-31 | -16,186,000 | USD | 2025-04-15 |
| Capital expenditure payments | 2024-01-01 | 2024-12-31 | 22,000 | USD | 2025-04-15 |
| Contract revenue excluding tax | 2024-01-01 | 2024-12-31 | 601,000 | USD | 2025-04-15 |
| Financing cash flow | 2024-01-01 | 2024-12-31 | 15,780,000 | USD | 2025-04-15 |
| Investing cash flow | 2024-01-01 | 2024-12-31 | -22,000 | USD | 2025-04-15 |
| Retained earnings or deficit | At date | 2024-12-31 | -358,561,000 | USD | 2025-04-15 |
| Basic weighted-average shares | 2024-01-01 | 2024-12-31 | 2,098,947 | shares | 2025-04-15 |
| Diluted weighted-average shares | 2024-01-01 | 2024-12-31 | 2,098,947 | shares | 2025-04-15 |
| Basic earnings per share | 2024-01-01 | 2024-12-31 | -8.88 | USD/shares | 2025-04-15 |
| Diluted earnings per share | 2024-01-01 | 2024-12-31 | -8.88 | USD/shares | 2025-04-15 |
| Net property, plant and equipment | At date | 2024-12-31 | 65,000 | USD | 2025-04-15 |
| Share-based compensation expense | 2024-01-01 | 2024-12-31 | 341,000 | USD | 2025-04-15 |
| Operating income or loss | 2024-01-01 | 2024-12-31 | -18,735,000 | USD | 2025-04-15 |
| Current assets | At date | 2024-12-31 | 2,531,000 | USD | 2025-04-15 |
| Interest expense | 2024-01-01 | 2024-12-31 | 2,000 | USD | 2025-04-15 |
| Current liabilities | At date | 2024-12-31 | 5,084,000 | USD | 2025-04-15 |
| Current accounts payable | At date | 2024-12-31 | 3,955,000 | USD | 2025-04-15 |
| Net current accounts receivable | At date | 2024-12-31 | 838,000 | USD | 2025-04-15 |
| Cost of revenue | 2020-01-01 | 2020-12-31 | 2,000 | USD | 2022-03-31 |
| Research and development expense | 2024-01-01 | 2024-12-31 | 12,545,000 | USD | 2025-04-15 |
Inspect the source
- Entity
- Vaccinex, Inc. / CIK 0001205922
- Captured
- 2026-09-19T11:16:57.889Z
- SEC response SHA-256
7972b50a3421e4dd4d1c4c3f4654af8f4df16f17dec50ed24ec25491e6d46a58
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001205922.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))